Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

Core Insights - Tevogen Bio Holdings Inc. has reiterated investor confidence and estimated its asset value to exceed $10 billion [1] - The company was recognized as the highest-valued biotech unicorn at $4.2 billion in 2022 [2] - Tevogen's leadership has achieved key milestones, including granted patents and a diverse product pipeline in multiple therapeutic areas [2] Company Valuation - HMP Partners and The Patel Family LLP estimate that Tevogen's current market value of its intellectual property and product portfolio exceeds $10 billion, excluding other assets [2] - The company is expected to have significant revenue potential due to advancements such as positive proof-of-concept clinical trials [2] - Tevogen's proprietary valuation model highlights the potential of its platform technologies and artificial intelligence initiatives [2]